Abstract
Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the induction of cytokine release and expansion of tumour-specific lymphocyte populations. In phase I studies, tumour responses have been observed in patients with malignant melanoma, lymphoma and ovarian carcinoma. The dose-limiting toxicity is myalgia. Sixteen patients (age 35-76 years, median 57 years) with malignant melanoma were treated. All had received prior chemotherapy. In each cycle of treatment, patients received bryostatin 25 degrees g m(-2) weekly for three courses followed by a rest week. The drug was given in PET diluent (10 microg bryostatin ml(-1) of 60% polyethylene glycol, 30% ethanol, 10% Tween 80) and infused in normal saline over 1 h. The principal toxicities were myalgia (grade 2, eight patients and grade 3, six patients) and grade 2 phlebitis (four patients), fatigue (three patients) and vomiting (one patient). Of 15 patients evaluable for tumour response, 14 developed progressive disease. One patient developed stable disease for 9 months after bryostatin treatment. In conclusion, single-agent bryostatin appears ineffective in the treatment of metastatic melanoma in patients previously treated with chemotherapy. It should, however, be investigated further in previously untreated patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Propper, D., Macaulay, V., O'Byrne, K. et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78, 1337–1341 (1998). https://doi.org/10.1038/bjc.1998.680
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.680
This article is cited by
-
Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism
Scientific Reports (2015)
-
Considerations of the chemical biology of microbial natural products provide an effective drug discovery strategy
Archives of Pharmacal Research (2015)
-
Protein kinase C, an elusive therapeutic target?
Nature Reviews Drug Discovery (2012)
-
Drug development from marine natural products
Nature Reviews Drug Discovery (2009)
-
Targeting the protein kinase C family: are we there yet?
Nature Reviews Cancer (2007)